diabetic retinopathy

Overview

Diabetic retinopathy is a diabetes-related microvascular disease of the retina and a major cause of visual impairment and blindness worldwide, particularly among working-age adults and older populations. It arises from chronic metabolic injury to the retinal microvasculature, with early events including pericyte loss, breakdown of the vascular barrier, endothelial dysfunction, inflammation, and abnormal vascular remodeling. As the disease progresses, it can advance to vision-threatening diabetic retinopathy and proliferative diabetic retinopathy, the latter being associated with irreversible complications.

Biologically, diabetic retinopathy is closely linked to hyperglycemia, dysregulated glucose and lipid metabolism, oxidative stress, inflammatory signaling, and angiogenic pathways such as VEGFA-mediated responses. Recent studies also implicate molecular regulators including WIF1, HIF1α/PFKFB3 signaling, ANGPTL4, PTTG1, and VE-cadherin phosphorylation in retinal vascular injury and repair. Because diabetic retinopathy can occur even in patients with apparently well-controlled HbA1c, current research increasingly emphasizes broader glycation-related, inflammatory, and metabolic contributors, as well as improved screening and Targeted therapies.

Focus of Latest Publications

Recent publications have examined diabetic retinopathy from several complementary angles: prevention, screening, prognosis, pathobiology, and treatment development.

A prospective cohort study reported that automated insulin delivery (AID) systems may reduce the risk of diabetic retinopathy in adults with type 1 diabetes compared with multiple daily injections (MDI). This work places glycemic management technology in the context of long-term microvascular protection, reinforcing the importance of sustained metabolic control in limiting retinal complications.

Several studies focused on molecular mechanisms underlying retinal injury and pathological angiogenesis. One investigation identified HMGA1 lactylation as a regulator of the SP1/VEGFA axis in pathological angiogenesis, highlighting a transcriptional and epigenetic route to VEGFA upregulation. Another study examined the cGAS-STING pathway in retinal pigment epithelial dysfunction, suggesting that innate immune signaling contributes to retinal cell injury in diabetic retinopathy. A separate report described myeloid cell protein tyrosine phosphatase 1B as a driver of retinal neurodegeneration in diabetic mice, supporting a role for immune-metabolic signaling in neuronal damage. Additional mechanistic work showed that TNF-α combined with high glucose aggravates endoplasmic reticulum stress in endothelial cell injury through calnexin, and that targeting Canx, including via repurposing adalimumab, may suppress pathological VEGFA production at its source.

Endothelial dysfunction and vascular barrier disruption were recurring themes. One study found that disrupting VE-cadherin Y685 phosphorylation inhibits development of experimental diabetic and prediabetic retinopathy, indicating that early vascular junction instability is a key initiating event. Another study reported that PTTG1 targeting in pericytes restores vascular integrity in diabetic retina, consistent with the central role of pericyte loss in early disease. Related work on DNMT1, FBXO32, MYC stability, and glycolytic reprogramming in diabetic retinopathy-associated endothelial cells further emphasized metabolic remodeling in vascular pathology. Wnt inhibitory factor 1 was also reported to inhibit glycolysis through the HIF1α/PFKFB3 signaling pathway, thereby modulating macrophage polarization and alleviating diabetic retinopathy, linking immune-cell behavior to retinal metabolic stress.

Inflammation and angiogenesis were also addressed through biomarker and signaling studies. ANGPTL4 was shown to induce aberrant lymphatic-like remodeling in proliferative diabetic retinopathy, a finding relevant to advanced neovascular disease. Inflammatory biomarkers were evaluated as prognostic tools for progression, and aqueous humour studies examined DEL-1 and IL-17 in diabetic cataract patients without retinopathy, reflecting interest in ocular inflammatory mediators such as IL17A and interleukin-6. These studies align with broader evidence that anti-inflammatory cytokines, proinflammatory cytokines, reactive oxygen species, superoxide dismutase, and growth factors such as TGF-β1 and VEGF participate in disease progression.

Therapeutic research remains active. VEGFA-targeted M3-F4 ionizable lipid nanoparticles were reported to improve diabetic retinopathy, supporting targeted delivery approaches to suppress angiogenic signaling. A study of prostacyclin analogs in patients with pulmonary hypertension assessed whether this therapy influences long-term diabetic retinopathy incidence, reflecting interest in systemic medications that may affect retinal microvascular outcomes. Another study evaluated a traditional formulation, Yigan Mingmu decoction, and proposed that it treats diabetic retinopathy via Müller cell autophagy. Vitexin was also reported to ameliorate high glucose-induced injury in ARPE-19 cells by targeting CASP3, and Vasant Kusumakar Rasa reduced neovascularization, oxidative stress, and inflammation while improving retinal function in diabetic rats. Together, these studies suggest that anti-vascular endothelial growth factor therapy, antioxidant strategies, autophagy modulation, and cell-protective interventions remain important therapeutic directions.

Diagnostic and screening research has expanded substantially. AI-assisted diabetic retinopathy screening in primary care was prospectively validated against ophthalmologist-led screening, and another study compared diagnostic agreement between an artificial intelligence system and general practitioners using non-mydriatic fundus photography. A related analysis involved Clinical Decision-Support Systems and highlighted diabetic retinopathy as a use case for AI-enabled care pathways. Quantitative optical coherence tomography angiography was used to assess retinal capillary plexuses and the influence of phakic versus pseudophakic status, while fundus autofluorescence imaging and fundus photographs remain important imaging modalities in screening and phenotyping. A study on nanostructured high-entropy yolk-shell oxides for metabolic profiling emphasized that diagnosis is still challenged by reliance on subjective interpretation of retinal images, underscoring the need for objective biomarkers and computational tools.

Population-level and risk-factor studies also contributed to the literature. Long-term incidence and progression of vision-threatening diabetic retinopathy were evaluated in Asian populations, and albumin-corrected fructosamine was associated with diabetic retinopathy in well-controlled type 2 diabetes, suggesting that glycation-related factors beyond HbA1c may matter. A multi-cohort dietary analysis found that higher plant-based diet quality was associated with lower risk of diabetic retinopathy, whereas less healthy plant-based patterns were associated with increased risk. Another study linked inflammatory biomarkers to progression in adults with recently diagnosed type 2 diabetes. These findings reinforce the importance of metabolic, inflammatory, and lifestyle determinants in disease risk.

Key Publications

• NEWJul Automated Insulin Delivery Reduces the Risk of Diabetic Retinopathy in Adults with Type 1 Diabetes: A Prospective Cohort Study. (Diabetes technology & therapeutics, 2026, PMID 41645537): "To evaluate the impact of automated insulin delivery (AID) systems on the incidence and progression of diabetic retinopathy (DR) in adults with type 1 diabetes (T1D) compared with multiple daily injections (MDI)."
• NEWJul HMGA1 Lactylation-Mediated Regulation of the SP1/VEGFA Axis in Pathological Angiogenesis Under Diabetic Retinopathy. (Diabetes, 2026, PMID 42102382): "Diabetic retinopathy (DR), a major complication of diabetes that causes blindness, is characterized by hyperglycemia-induced vascular dysfunction of incompletely defined mechanisms."
• NEWJul cGAS-STING Pathway Mediates Retinal Pigmental Epithelial Dysfunction in Diabetic Retinopathy. (Diabetes, 2026, PMID 42149122): "Diabetic retinopathy (DR) is a predominant cause of vision impairment among working-age individuals, with a subset of patients responding poorly to current treatments."
• Jul Myeloid Cell Protein Tyrosine Phosphatase 1B Drives Retinal Neurodegeneration in Diabetic Mice. (Diabetes, 2026, PMID 42166617): "Diabetic retinopathy (DR) is the leading cause of vision loss in the working-age population, with public health economic implications worldwide."
• Jul PROSTACYCLIN ANALOGS AND DIABETIC RETINOPATHY OUTCOMES IN PATIENTS WITH PULMONARY HYPERTENSION : A Cohort Analysis. (Retina (Philadelphia, Pa.), 2026, PMID 42308470): "The aim of this study was to evaluate the association between prostacyclin analog (PCA) therapy and the long-term incidence of diabetic retinopathy (DR) in patients with diabetes and pulmonary arterial hypertension."
• Jul The Mechanism of TNF-α Combined With High Glucose in Regulating Calnexin Aggravates Endoplasmic Reticulum Stress in Endothelial Cell Injury of Diabetic Retinopathy. (Diabetes, 2026, PMID 42330304): "Our study suggests that targeting Canx, either genetically or via repurposing adalimumab, represents a source-specific strategy to halt DR progression by blocking pathological Vegfa production at its origin."
• Jul Quantitative optical coherence tomography angiography analysis of retinal capillary plexuses in diabetic eyes: Impact of phakic and pseudophakic status. (Indian journal of ophthalmology, 2026, PMID 42378082): "Diabetic retinopathy (DR) is associated with progressive microvascular rarefaction, but the effect of lens status on OCTA-derived vascular metrics remains underexplored."
• Jul Vitexin Ameliorates HG-Induced Injury in Retinal ARPE-19 Cells by Targeting CASP3. (Journal of biochemical and molecular toxicology, 2026, PMID 42345537): "Diabetic retinopathy (DR) stands as a common microvascular issue associated with diabetes mellitus, a condition defined by progressive structural decline in the retina."
• Jun DNMT1 methylates E3 ligase FBXO32 to regulate Myc stability and glycolytic reprogramming in diabetic retinopathy associated endothelial cells. (Journal of bioenergetics and biomembranes, 2026, PMID 42348038): "...its role and regulatory network in DR-associated endothelial dysfunction are unclear."
• Jun Levels of DEL-1 and IL-17 in the aqueous humor of cataract patients with diabetes without diabetic retinopathy. (International ophthalmology, 2026, PMID 42347979): "IL-17 is a proinflammatory cytokine implicated in diabetes-related microvascular and ocular inflammatory processes, particularly in diabetic retinopathy."